References
- Von Hoff D D, Schilsky R, Reichart C M, et al. Toxic effects of cisdichlorodiamineplatinum (II) in man. Cancer Treat Rep 1979; 63: 1527–1531
- Helson L, Okonkwo E, Anton L, et al. Cis-platinum ototoxicity. Clin Toxicol 1978; 13: 469–478
- Reddel R R, Kofford R F, Grant J M, et al. Ototoxicity in patients receiving cisplatin: Importance of dose and method of drug administration. Cancer Treat Rep 1982; 66: 19–23
- Fleming S M, Peters G M, Weaver A W, et al. Ototoxicity associated with cisplatinum in three chemotherapy multi drug regimens. Cancer 1983; 51: 610–613
- Ozols R F, Ostchega Y, Myers C E, Young R C. High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol 1985; 3: 1246–1250
- Gilden L., Ruiz J, Jaffe N, et al. Auditory function in pediatric osteosarcoma patients treated with multiple doses of cis-diamminedichloroplatinum (II). Cancer Res 1989; 49: 742–744
- Boyer M, Raghaven D, Harrie P J, et al. Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular carcinoma. J Clin Oncol 1990; 8: 21–26
- Vermorken J B, Kapteijn T S, Hart A AM, et al. Ototoxicity of cis-diamminedichloroplatinum (II): Influence of dose, schedule and mode of administration. Eur J Cancer Clin Oncol 1983; 18: 53–58
- Stadnicki S, Fleischman R, Schaeppi M, et al. Cis-dichlorodiammine platinum (II) (NSC-119875): Hearing loss and other toxic effects in rhesus monkeys. Cancer Chemother Rep 1975; 59: 467–480
- Dolowitz D A, Stephens F E. Hereditary nerve deafness. Ann Otol Rhinol 1961; 70: 851–859
- Martensson B. Dominant hereditary nerve deafness. Acta Otolaryngol 1960; 52: 270–274
- Schuknecht H F. Pathology of the Ear. Harvard University Press, Cambridge, MA 1974; 168
- Teig E. Hereditary progressive perceptive deafness in a family of 72 patients. Acta Otolaryngol 1968; 65: 365–372